BBTX
Bambusa Therapeutics, Inc. Common stock
Price Chart
Latest Quote
$14.99
-1.01 (-6.31%)
Current Price
| Previous Close | $16.00 |
| Open | $14.88 |
| Day High | $15.66 |
| Day Low | $13.60 |
| Volume | 2,200,049 |
Stock Information
| Shares Outstanding | 49.76M |
| Cash Equivalents | $71.47M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $745.93M |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $184.82M |
| Book/sh | $-8.86 |
| Cash/sh | $1.44 |
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | -1.69 |
Analyst Data
| Recommendation | none |
Technical Indicators
Performance History
| YTD | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-30 | $14.99 | 2,200,100 |
About Bambusa Therapeutics, Inc. Common stock
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United States, Australia, New Zealand, China, Europe, and internationally. Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.
đ° Latest News
No news articles available at the moment. Check back later for updates on BBTX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $40,696,000 | $13,880,000 |
| Other Income Expense | $-329,000 | $8,000 |
| Other Non Operating Income Expenses | $125,000 | $8,000 |
| Net Non Operating Interest Income Expense | $2,171,000 | $131,000 |
| Operating Expense | $40,696,000 | $13,880,000 |
| Other Operating Expenses | $-3,310,000 | - |
| General And Administrative Expense | $5,910,000 | $855,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-41,087,000 | $-13,741,000 |
| Net Interest Income | $2,171,000 | $131,000 |
| Interest Income | $2,171,000 | $131,000 |
| Normalized Income | $-40,749,088 | $-13,741,000 |
| Net Income From Continuing And Discontinued Operation | $-41,087,000 | $-13,741,000 |
| Total Operating Income As Reported | $-44,006,000 | $-13,880,000 |
| Net Income Common Stockholders | $-41,087,000 | $-13,741,000 |
| Net Income | $-41,087,000 | $-13,741,000 |
| Net Income Including Noncontrolling Interests | $-41,087,000 | $-13,741,000 |
| Net Income Continuous Operations | $-41,087,000 | $-13,741,000 |
| Pretax Income | $-38,854,000 | $-13,741,000 |
| Interest Income Non Operating | $2,171,000 | $131,000 |
| Operating Income | $-40,696,000 | $-13,880,000 |
| Per Share | ||
| Diluted EPS | $-1.92 | $-0.59 |
| Basic EPS | $-1.92 | $-0.59 |
| Other | ||
| Tax Effect Of Unusual Items | $-116,088 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-40,242,000 | $-13,880,000 |
| Total Unusual Items | $-454,000 | - |
| Total Unusual Items Excluding Goodwill | $-454,000 | - |
| EBITDA (Bullshit earnings) | $-40,696,000 | $-13,880,000 |
| EBIT | $-40,696,000 | $-13,880,000 |
| Diluted Average Shares | $21,439,565 | $23,380,436 |
| Basic Average Shares | $21,439,565 | $23,380,436 |
| Diluted NI Availto Com Stockholders | $-41,087,000 | $-13,741,000 |
| Tax Provision | $2,233,000 | $0 |
| Gain On Sale Of Security | $-454,000 | - |
| Research And Development | $38,096,000 | $13,025,000 |
| Selling General And Administration | $5,910,000 | $855,000 |
| Other Gand A | $5,910,000 | $855,000 |
Fetched: 2026-10-31
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-49,170,000 | $-13,548,000 |
| Total Assets | $95,713,000 | $9,764,000 |
| Total Non Current Assets | $1,581,000 | $0 |
| Other Non Current Assets | $1,581,000 | - |
| Current Assets | $94,132,000 | $9,764,000 |
| Other Current Assets | $583,000 | $94,000 |
| Prepaid Assets | $1,040,000 | $275,000 |
| Receivables | $1,882,000 | $33,000 |
| Other Receivables | $1,097,000 | - |
| Taxes Receivable | $785,000 | $33,000 |
| Cash Cash Equivalents And Short Term Investments | $90,627,000 | $9,362,000 |
| Cash And Cash Equivalents | $50,643,000 | $9,362,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $144,883,000 | $23,312,000 |
| Total Non Current Liabilities Net Minority Interest | $135,235,000 | $13,996,000 |
| Current Liabilities | $9,648,000 | $9,316,000 |
| Payables And Accrued Expenses | $8,859,000 | $9,107,000 |
| Payables | $1,905,000 | $13,000 |
| Accounts Payable | $1,905,000 | $13,000 |
| Equity | ||
| Common Stock Equity | $-49,170,000 | $-13,548,000 |
| Total Equity Gross Minority Interest | $-49,170,000 | $-13,548,000 |
| Stockholders Equity | $-49,170,000 | $-13,548,000 |
| Gains Losses Not Affecting Retained Earnings | $60,000 | $0 |
| Other Equity Adjustments | $60,000 | - |
| Retained Earnings | $-54,828,000 | $-13,741,000 |
| Preferred Securities Outside Stock Equity | $135,235,000 | $13,996,000 |
| Other | ||
| Tangible Book Value | $-49,170,000 | $-13,548,000 |
| Invested Capital | $-49,170,000 | $-13,548,000 |
| Working Capital | $84,484,000 | $448,000 |
| Total Capitalization | $-49,170,000 | $-13,548,000 |
| Additional Paid In Capital | $5,598,000 | $193,000 |
| Capital Stock | $0 | $0 |
| Common Stock | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $789,000 | $209,000 |
| Current Accrued Expenses | $6,954,000 | $9,094,000 |
| Other Short Term Investments | $39,984,000 | $0 |
Fetched: 2026-10-31
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-39,804,000 | $-4,634,000 |
| Operating Activities | ||
| Operating Cash Flow | $-39,804,000 | $-4,634,000 |
| Cash Flow From Continuing Operating Activities | $-39,804,000 | $-4,634,000 |
| Operating Gains Losses | $-71,000 | $-8,000 |
| Investing Activities | ||
| Investing Cash Flow | $-39,728,000 | $0 |
| Cash Flow From Continuing Investing Activities | $-39,728,000 | $0 |
| Financing Activities | ||
| Issuance Of Capital Stock | $120,813,000 | $13,996,000 |
| Financing Cash Flow | $120,813,000 | $13,996,000 |
| Cash Flow From Continuing Financing Activities | $120,813,000 | $13,996,000 |
| Net Preferred Stock Issuance | $120,785,000 | $13,996,000 |
| Preferred Stock Issuance | $120,785,000 | $13,996,000 |
| Net Common Stock Issuance | $28,000 | $0 |
| Common Stock Issuance | $28,000 | $0 |
| Other | ||
| End Cash Position | $50,643,000 | $9,362,000 |
| Beginning Cash Position | $9,362,000 | $0 |
| Changes In Cash | $41,281,000 | $9,362,000 |
| Net Investment Purchase And Sale | $-39,728,000 | $0 |
| Sale Of Investment | $7,500,000 | $0 |
| Purchase Of Investment | $-47,228,000 | $0 |
| Change In Working Capital | $-4,281,000 | $8,922,000 |
| Change In Other Current Assets | $-1,567,000 | $0 |
| Change In Payables And Accrued Expense | $349,000 | $9,316,000 |
| Change In Accrued Expense | $-1,557,000 | $9,303,000 |
| Change In Payable | $1,906,000 | $13,000 |
| Change In Account Payable | $1,906,000 | $13,000 |
| Change In Prepaid Assets | $-3,063,000 | $-394,000 |
| Other Non Cash Items | $454,000 | - |
| Stock Based Compensation | $5,377,000 | $193,000 |
| Amortization Of Securities | $-196,000 | $0 |
| Net Foreign Currency Exchange Gain Loss | $-71,000 | $-8,000 |
| Net Income From Continuing Operations | $-41,087,000 | $-13,741,000 |
Fetched: 2026-10-31